fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

People living with HIV at substantially higher risk of depression and suicide, especially in first 2 years after diagnosis

Written by | 9 Apr 2023

People living with HIV (PLWH) are far more likely to be diagnosed with depression, take antidepressants, be treated with electroconvulsive therapy, and commit suicide than population controls, especially… read more.

Early HIV diagnosis and treatment important for better long-term health outcomes

Written by | 30 Oct 2022

Starting antiretroviral treatment (ART) early in the course of HIV infection when the immune system is stronger results in better long-term health outcomes compared with delaying ART, according… read more.

Patient possibly cured of HIV infection by special stem-cell transplant

Written by | 23 Feb 2022

A patient living with HIV who received a blood stem cell transplant for high-risk acute myeloid leukemia has been free of the virus for 14 months after stopping… read more.

Phase III CARISEL study of Vocabria + Rekambys shows long-acting regimen is achievable in HIV – ViiV Healthcare

Written by | 9 Feb 2022

ViiV Healthcare presented positive interim data from the Phase III CARISEL study of Vocabria + Rekambys (cabotegravir + rilpivirine), which was initiated and conducted during the COVID-19 pandemic…. read more.

FDA application for first dispersible single tablet regimen containing dolutegravir (DTG) for children living with HIV – ViiV HealthCare

Written by | 7 Jan 2022

ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, has announced it has made a regulatory submission to the… read more.

ViiV Healthcare submits extended approval request for tablet formulation of Triumeq for HIV to FDA

Written by | 18 Oct 2021

ViiV Healthcare has announced it has made a regulatory submission to the FDA for approval of a new dispersible tablet formulation of the fixed dose combination of abacavir,… read more.

Four-year Biktarvy data presented at IAS 2021 demonstrate high efficacy and durable viral suppression in treatment-naïve adults with HIV – Gilead Sciences

Written by | 29 Jul 2021

Gilead Sciences, Inc. announced a pooled analysis of a 48-week open-label extension of two Phase III studies (Study 1489 and Study 1490) shows 99% of participants who initiated… read more.

Young male students at the centre of HIV surge

Written by | 20 Jul 2021

There has been a rapid rise in the number of human immunodeficiency virus (HIV) infections in China since the dawn of the 21st century. In the recent past,… read more.

How HIV infection shrinks the brain’s white matter

Written by | 19 Jun 2021

It’s long been known that people living with HIV experience a loss of white matter in their brains. As opposed to “gray matter,” which is composed of the… read more.

Mobile gaming app enhances HIV care

Written by | 16 May 2021

Article written by Gary Finnegan. Survival rates among people living with HIV have soared over several decades, thanks to antiretroviral therapies. However, as maintaining long-term treatment can be… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.